Gout is an inflammatory crystal arthritis characterised by hyperuricaemia and deposition of monosodium urate crystals (MSU) into joints and soft tissues. Urate-lowering therapy (ULT) is the cornerstone of long term managing chronic hyperuricemia and recurrent flares in patients with chronic tophaceous gout. Early ULT results in suppression of serum uric acid (SUA) and dissolution of deposited MSU crystals and tophi, thus preventing joint erosion complications.